J Thorac Dis. 2026 May 31;18(5):512. doi: 10.21037/jtd-2025-1-2719. Epub 2026 Apr 26.
ABSTRACT
BACKGROUND: The optimal timing of thoracic radiotherapy (RT) during concurrent chemoradiotherapy (CCRT) for small cell lung cancer (SCLC) remains controversial. This study aimed to evaluate treatment outcomes, prognostic factors, and the role of prophylactic cranial irradiation (PCI) according to thoracic RT timing in patients with limited-disease (LD) SCLC.
METHODS: A retrospective study was conducted on patients with SCLC diagnosed between 2018 and 2022. Survival outcomes, prognostic factors, treatment outcomes, and adverse events were assessed according to thoracic RT timing (early vs. late) and PCI use.
RESULTS: Among 122 patients diagnosed with LD-SCLC, 99 who received CCRT were included in the analysis, comprising 74 patients in the early thoracic RT (ERT) and 25 in the late thoracic RT (LRT) group. After propensity score matching (PSM) based on RT timing, Kaplan-Meier survival analysis demonstrated that the ERT group had significantly longer median overall survival (OS) (20.0 vs. 12.0 months, P=0.041) and progression-free survival (PFS) (16.0 vs. 8.0 months, P=0.01) than the LRT group, whereas brain metastasis-free survival (BMFS) did not differ significantly (P=0.32). Following PSM according to PCI status, OS and PFS were comparable between groups; however, BMFS was significantly longer in the PCI group (P=0.048). In multivariate Cox analysis, both age and thoracic RT timing remained significant prognostic factors for OS and PFS. No statistically significant differences were observed in treatment response or treatment-related adverse events between groups.
CONCLUSIONS: In patients with LD-SCLC treated with CCRT, ERT was associated with improved survival without a significant increase in treatment-related toxicity. Although PCI did not confer a clear survival benefit, it may reduce the risk of brain metastasis.
PMID:42306720 | PMC:PMC13266864 | DOI:10.21037/jtd-2025-1-2719